reserpine has been researched along with alpha-synuclein in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alessandrí, MG; Fornai, F; Geppert, M; Jahn, R; Schlüter, OM; Südhof, TC; Takamori, S | 1 |
| Cooper, JM; Korlipara, LV; Messmer, K; Orth, M; Schapira, AH; Tabrizi, SJ; Tomlinson, C | 1 |
| Antonio, T; Dutta, AK; Gogoi, S; Modi, G; Reith, ME; Shah, M; Voshavar, C | 1 |
| Downing, TG; van Onselen, R | 1 |
| Beserra-Filho, JIA; Custódio-Silva, AC; de Souza Araújo, AA; Lambertucci, RH; Lucchese, AM; Maria-Macêdo, A; Quintans-Júnior, LJ; Ribeiro, AM; Santos, JR; Silva, RH; Silva, SP; Silva-Martins, S; Soares-Silva, B | 1 |
| Abílio, VC; Bincoletto, C; Carneiro, CA; Crippa, JA; da Cruz Guedes, E; Erustes, AG; Hallak, JEC; Leão, AHFF; Pereira, GJS; Reckziegel, P; Smaili, SS; Zuardi, AW | 1 |
6 other study(ies) available for reserpine and alpha-synuclein
| Article | Year |
|---|---|
Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; alpha-Synuclein; Animals; Antibodies; Blastomeres; Blotting, Southern; Corpus Striatum; Disease Models, Animal; DNA Primers; Dopamine; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Glutamic Acid; Hippocampus; Homovanillic Acid; Humans; Immunoblotting; Immunohistochemistry; Methamphetamine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; MPTP Poisoning; Nerve Tissue Proteins; Neurons; Parkinsonian Disorders; Piperazines; Rats; Reserpine; Serotonin; Stem Cells; Subcellular Fractions; Substantia Nigra; Synucleins; Tyrosine 3-Monooxygenase | 2003 |
G209A mutant alpha synuclein expression specifically enhances dopamine induced oxidative damage.
Topics: Aconitate Hydratase; Adrenergic Uptake Inhibitors; alpha-Synuclein; Blotting, Western; Cell Line; Cells, Cultured; Dopamine; Ecdysterone; Glutathione; Herbicides; Humans; Immunohistochemistry; Mutation; Nerve Tissue Proteins; Oxidative Stress; Paraquat; Reserpine; Synucleins | 2004 |
Multifunctional D2/D3 agonist D-520 with high in vivo efficacy: modulator of toxicity of alpha-synuclein aggregates.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Cell Line, Tumor; Cell Survival; CHO Cells; Cricetulus; Dopamine Agonists; Dopaminergic Neurons; HEK293 Cells; Humans; Male; Mice; Molecular Structure; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Rats, Sprague-Dawley; Receptors, Dopamine D3; Reserpine | 2014 |
Neonatal Reserpine Administration Produces Widespread Neuronal Losses and ⍺-Synuclein Inclusions in a Rat Model.
Topics: alpha-Synuclein; Animals; Brain; Female; Inclusion Bodies; Neurons; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Sprague-Dawley; Reserpine | 2021 |
Lippia grata essential oil complexed with β-cyclodextrin ameliorates biochemical and behavioral deficits in an animal model of progressive parkinsonism.
Topics: alpha-Synuclein; Animals; Antioxidants; beta-Cyclodextrins; Disease Models, Animal; Dopaminergic Neurons; Lippia; Neuroprotective Agents; Oils, Volatile; Parkinson Disease; Parkinsonian Disorders; Reserpine; Substantia Nigra | 2022 |
Cannabidiol Recovers Dopaminergic Neuronal Damage Induced by Reserpine or α-synuclein in Caenorhabditis elegans.
Topics: Aged; alpha-Synuclein; Animals; Animals, Genetically Modified; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Cannabidiol; Disease Models, Animal; Dopaminergic Neurons; Humans; Neurodegenerative Diseases; Neuroprotective Agents; Parkinson Disease; Receptors, G-Protein-Coupled; Reserpine | 2023 |